The seventh annual BioPharm America™ international life science partnering conference will be held September 22–24 at Boston Marriott Copley Place in the center of Boston’s historic Back Bay. The event is a big draw for pharma and investors who want to access innovative new potential therapies and cures brought by international biotech companies.
“Today is a great time for venture capital investments in innovative technologies that are tackling big, unmet problems in healthcare,” said Brian Gallagher, Partner at SR One. “Many recent exits and new funds raised are increasing the appetite for investments in exciting new biotech startups, which I’m sure will result in a strong investor turnout at BioPharm America this year.”
The investment climate is excellent in 2014, and venture capital attendance at BioPharm America will be stronger than ever. Investors already confirmed to attend include: Philip Astley-Sparke, Venture Partner at Forbion Capital Partners; Peter Barrett, Partner, Atlas Venture; Cedric Bisson, Venture Partner at Teralys Capital; Bruce Booth, Partner at Atlas Venture; Bernard Davitian, VP and Managing Director at Sanofi-Genzyme BioVentures, Sanofi; Todd Foley, Managing Director at MPM Capital; Brian Gallagher, Partner, at SR One; Jim Geraghty, Entrepreneur-in-Residence at Third Rock Ventures; Frederick Jones, Director at Broadview Ventures, Inc.; Nilesh Kumar, Director at MS Ventures; Dan Liu, Senior Associate at Mitsui Global Investment; Ed Mathers, Partner at New Enterprise Associates; Takahiro Mukohira, President at MP Healthcare Venture Management; Liam Ratcliffe; Managing Director at New Leaf Venture Partners; Kevin Starr, Partner at Third Rock Ventures; and Robert Weisskoff, Partner at Fidelity Biosciences.
“2014 has been a productive year for biotech, with some significant regulatory approvals and biotech IPOs performing pretty well. We are seeing many interesting and potentially groundbreaking scientific developments,” said Frederick Jones, Director at Broadview Ventures, Inc., a philanthropic venture fund focused on early stage companies with highly innovative cardiovascular and neurovascular technologies. “The remainder of 2014 still holds a lot of potential for some interesting alliances. It’s going to make BioPharm America an exciting place to be this year.”
Presenting companies at BioPharm America represent some of the most innovative companies ranging from early stage projects and small entrepreneurial companies, to established biotech companies. The 2014 list includes Acetylon Pharmaceuticals, Inc.; AnaptysBio, Inc.; Apitope; Avexxin AS; Cerecor Inc.; Cerulean Pharma Inc.; Charleston Laboratories, Inc.; Dicerna; Gene Signal ; Igenica Biotherapeutics; Poxel SA; RedHill Biopharma; Rexahn Pharmaceuticals; RXi Pharmaceuticals; Selvita S.A.; uniQure; and Vaccinex, Inc, among many more.
More than 900 delegates representing 550 companies from 35 countries participated in BioPharm America 2013. Delegates in 2013 engaged in 2,950 one-to-one partnering meetings and identified 757 potential licensing opportunities.
BioPharm America is produced by EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) to facilitate strategic collaborations with leading companies. One-to-one networking at BioPharm America™ is powered by partneringONE®, the leading conference networking solution for the life sciences.
Register now to attend the largest dedicated partnering event in the eastern US. Partnering is already open.